🎁 💸 Warren Buffett's Top Picks Are Up +49.1%. Copy Them to Your Watchlist – For FreeCopy Portfolio

Australia sees no changes to COVID-19 vaccine rollout plans after UK approval

Published 03/12/2020, 09:20 am
Updated 03/12/2020, 09:24 am
© Reuters
CSL
-
AZN
-
PFE
-
NVAX
-

SYDNEY, Dec 3 (Reuters) - Australia expects no changes to the timeline for its COVID-19 vaccine rollout plans, Health Minister Greg Hunt said, after Britain approved Pfizer Inc (NYSE:PFE)'s PFE.N vaccine on Wednesday, the first country to do so.

Britain said it would start inoculating high-risk people from early next week with the vaccine, developed by Pfizer and German partner BioNTech SE 22UAy.DE . advice remains that the timeline for a decision on approval is expected by the end of January 2021, and our planning is for first vaccine delivery in March 2021," Hunt said in a statement issued late Wednesday.

Pfizer's is one of the four COVID-19 vaccines the Australian government has agreed to buy for a total projected supply of nearly 135 million doses. It has already committed to buy vaccines from Novavax NVAX.O , AstraZeneca AZN.L and CSL Ltd CSL.AX should trials prove successful.

Australia has largely contained the community transmission of the virus but New South Wales (NSW), its largest state, on Thursday reported a new case for the first time in nearly a month after a hotel quarantine worker tested positive.

Five family members of the worker were tested overnight and all returned a negative result for the virus, NSW Health Minister Brad Hazzard told broadcaster Seven News.

The report of the new case comes a day after NSW eased a raft of restrictions at weddings, bars and dancing venues marking the biggest lifting of curbs since March when lockdowns were enforced to slow the spread of COVID-19. has reported nearly 28,000 cases of COVID-19 and 908 deaths since the pandemic began but estimates there are fewer than 100 active cases remaining, mostly returned travelers from overseas in hotel quarantine.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.